UGPA3:BMFBOVESPAUltrapar Participacoes S.A. Analysis
Data as of 2026-03-15 - not real-time
R$26.12
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Ultrapar (UGPA3) is trading at R$26.12, comfortably above the 20‑day SMA (R$26.66) and well above the 50‑day SMA (R$24.88), confirming a bullish price structure that sits between a clear support at R$24.70 and resistance near R$28. Volume is increasing and the 30‑day volatility of 25% suggests ample price movement potential. The RSI of 50 indicates a neutral momentum, while the MACD histogram is negative, hinting at a short‑term pull‑back within the broader uptrend. Valuation metrics are attractive: a trailing P/E of 11.1 is roughly half the industry average of 22.2, and the price‑to‑book of 1.78 sits below the sector norm, though the DCF‑derived fair value of R$18.2 implies the market is pricing in growth and premium assets. Dividend yield stands at a robust 6.7% with a payout ratio of 74%, supported by solid operating cash flow (R$5.45 bn) and free cash flow (R$1.85 bn).
A material catalyst may emerge from the rumored divestiture of the Ipiranga unit, which analysts argue could unlock hidden value and reshape the fuel‑distribution dynamics. Revenue growth of 7.2% and a ROE of 16% demonstrate steady earnings improvement, yet the company carries a high debt‑to‑equity ratio of 123%, flagging balance‑sheet risk. The low beta of 0.34 points to limited market‑wide volatility, but sector‑specific regulatory and commodity risks remain. Overall, the blend of undervalued multiples, strong dividend income, and a potential strategic sale supports a cautiously optimistic outlook.
A material catalyst may emerge from the rumored divestiture of the Ipiranga unit, which analysts argue could unlock hidden value and reshape the fuel‑distribution dynamics. Revenue growth of 7.2% and a ROE of 16% demonstrate steady earnings improvement, yet the company carries a high debt‑to‑equity ratio of 123%, flagging balance‑sheet risk. The low beta of 0.34 points to limited market‑wide volatility, but sector‑specific regulatory and commodity risks remain. Overall, the blend of undervalued multiples, strong dividend income, and a potential strategic sale supports a cautiously optimistic outlook.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish SMA alignment and rising volume
- High dividend yield providing immediate income
- Support level at R$24.70 offering downside buffer
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Valuation upside of ~3.5% to analyst target around R$27
- Projected earnings growth and improving ROE
- Potential value unlock from Ipiranga sale
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Elevated debt‑to‑equity ratio increasing financial risk
- Energy sector regulatory and commodity price exposure
- Sustainable dividend stream offset by balance‑sheet concerns
Key Metrics & Analysis
Financial Health
Revenue Growth7.20%
Profit Margin1.72%
P/E Ratio11.1
ROE16.38%
ROA6.95%
Debt/Equity123.14
P/B Ratio1.8
Op. Cash FlowR$5.5B
Free Cash FlowR$1.9B
Industry P/E22.2
Technical Analysis
TrendBullish
RSI50.3
SupportR$24.70
ResistanceR$28.00
MA 20R$26.66
MA 50R$24.88
MA 200R$20.78
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Fair ValueR$18.21
Target PriceR$27.03
Upside/Downside3.46%
GradeFair
TypeBlend
Dividend Yield6.70%
Risk Assessment
Beta0.34
Volatility25.10%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.